AA
REGN icon

Apriem Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Apriem Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$271K Sell
434
-7,722
-95% -$5.26M 0.02% 162
2026
Q1 		$6.3M Sell
8,156
-428
-5% -$328K 0.6% 37
2025
Q4 		$6.63M Sell
8,584
-64
-0.7% -$43.5K 0.61% 37
2025
Q3 		$4.86M Sell
8,648
-469
-5% -$265K 0.46% 42
2025
Q2 		$4.79M Sell
9,117
-3,319
-27% -$1.85M 0.51% 42
2025
Q1 		$7.89M Sell
12,436
-2,058
-14% -$1.42M 0.92% 32
2024
Q4 		$10.3M Sell
14,494
-1,033
-7% -$867K 1.18% 25
2024
Q3 		$16.3M Sell
15,527
-806
-5% -$897K 1.91% 13
2024
Q2 		$17.2M Sell
16,333
-4,390
-21% -$4.26M 2.1% 9
2024
Q1 		$19.9M Sell
20,723
-3,095
-13% -$2.94M 2.51% 8
2023
Q4 		$20.9M Sell
23,818
-1,099
-4% -$905K 2.79% 9
2023
Q3 		$20.5M Sell
24,917
-685
-3% -$538K 3% 8
2023
Q2 		$18.4M Sell
25,602
-505
-2% -$389K 2.76% 8
2023
Q1 		$21.5M Sell
26,107
-5,265
-17% -$3.97M 3.43% 7
2022
Q4 		$22.6M Sell
31,372
-876
-3% -$646K 3.92% 6
2022
Q3 		$22.2M Buy
32,248
+28
+0.1% +$17.6K 4.01% 6
2022
Q2 		$19M Buy
32,220
+82
+0.3% +$53.3K 3.28% 8
2022
Q1 		$22.4M Buy
32,138
+386
+1% +$244K 3.29% 5
2021
Q4 		$20.1M Buy
+31,752
New +$19.5M 2.84% 10
2017
Q2 		– Sell
-25
Closed -$10K – 448
2017
Q1 		$10K Hold
25
– – ﹤0.01% 421
2016
Q4 		$9K Sell
25
-20
-44% -$7.61K ﹤0.01% 451
2016
Q3 		$18K Hold
45
– – 0.01% 344
2016
Q2 		$16K Hold
45
– – 0.01% 366
2016
Q1 		$16K Hold
45
– – 0.01% 330
2015
Q4 		$24K Hold
45
– – 0.01% 275
2015
Q3 		$21K Hold
45
– – 0.01% 290
2015
Q2 		$23K Buy
45
+20
+80% +$9.76K 0.01% 303
2015
Q1 		$11K Buy
+25
New +$10.6K ﹤0.01% 405

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Apriem Advisors's REGN Position: Q2 2026 in Review

Apriem Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 95% in Q2 2026, selling an estimated $5.26M and leaving 434 shares worth $271K. The position accounts for 0.02% of the portfolio, ranked #162.

Apriem Advisors first reported a position in REGN in Q1 2015 and has held it in 28 quarters since. The position peaked at $22.6M in Q4 2022. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Apriem Advisors held 434 shares of Regeneron Pharmaceuticals worth $271K as of Q2 2026.
  • Apriem Advisors sold 7,722 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $5.26M.
  • Regeneron Pharmaceuticals made up 0.02% of Apriem Advisors's portfolio in Q2 2026, its #162 holding.
  • Apriem Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2015 and has held it in 28 quarters since.
  • Apriem Advisors's Regeneron Pharmaceuticals position peaked at $22.6M in Q4 2022.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Apriem Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.